HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.